Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 33 recruiting now full pipeline

Sepsis: full-pipeline trial registry

33 of 91 indexed Sepsis trials are currently recruiting.

Corpus placement: #151 of 28,707 conditions by registered trial count.

91 US clinical trials · 33 currently recruiting · #151 of 28,707 conditions by registered trial count

Sepsis: 91 US clinical trials tracked, 33 recruiting.

Sepsis is the subject of 91 registered US clinical trials on ClinicalTrials.gov, 33 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is University of Florida, running 7 of these trials.

Enrollment posture brief

Registry condition sepsis

OPEN 33 | RECR 36% | LATE 10 | EARLY 14 | RANK #151 | SPON 7

Nearest open-share peer: Acquired Brain Injury (36% recruiting · 11 trials)

Cerebral Palsy48.9%Critical Illness44.6%Sepsis (this)36%Metastatic Melanoma34.8%Myopia24.2%
Open-enrollment share among volume-matched conditions near Sepsis

Sepsis lists 33 open slots (36% of 91 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sepsis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sepsis is recruiting below its size-band peers.

    33 of 91 indexed trials (36.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Sepsis trials is spread across many organizations.

    University of Florida accounts for 7 of 91 trials (7.7%). 65 distinct sponsors appear on at least one study for this condition label.

  3. Typical Sepsis enrolment sits around 186 participants.

    Median target enrolment is 186 among the 91 trials that report a genuine target (sentinel values excluded). 35 of those (38.5%) plan for fewer than 100 participants.

  4. Sepsis splits between interventional and observational designs.

    46 interventional and 45 observational studies make up this index (50.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 28Phase 36Phase 44

Open and recent trials

91 total, page 2 of 2

COMPLETED 1,055 participants

Evaluation of the Heparin Binding Protein Levels in Sepsis

Christiana Care Health Services

NCT02533011

COMPLETED 815 participants

Early Identification of SEPsis SIGNs in Emergency Department

BioMérieux

NCT04261621

COMPLETED 544 participants

Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis

Abionic

NCT04105699

COMPLETED 500 participants

Indicators of Inflammation and Coagulation in Sepsis

University of Oklahoma

NCT01128283

COMPLETED 500 participants

Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis

University of Oklahoma

NCT01012115

COMPLETED 477 participants

Evaluation of Infection in Obstructing Urolithiasis

University of Texas Southwestern Medical Center

NCT04332861

COMPLETED Phase 3 438 participants

The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure

Vanderbilt University Medical Center

NCT01739933

COMPLETED 379 participants

VENUS: Septic Gene Expression Using SeptiCyte

Immunexpress

NCT02127502

COMPLETED 350 participants

SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay

Karius

NCT02730468

COMPLETED NA 209 participants

A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders

University of Alabama at Birmingham

NCT03767517

COMPLETED Phase 1 208 participants

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

Cook County Health

NCT00130221

COMPLETED NA 200 participants

Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?

Jewish Hospital, Cincinnati, Ohio

NCT01878968

COMPLETED 200 participants

Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial

Inflammatix

NCT04414189

COMPLETED Phase 3 200 participants

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

Eli Lilly and Company

NCT00190788

COMPLETED NA 186 participants

Trial of Antimicrobial Restraint in Presumed Pneumonia

University of Kansas Medical Center

NCT04438187

COMPLETED 184 participants

Performance Evaluation of the Nanomix eLab® CRP, PCT, and LAC Assays With the Nanomix eLab System

Nanomix

NCT03876535

COMPLETED Phase 2 150 participants

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Altor BioScience

NCT00879606

COMPLETED 150 participants

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

Abionic

NCT04409561

COMPLETED NA 145 participants

Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

University of Pennsylvania

NCT02207114

COMPLETED NA 142 participants

Preemptive Resuscitation for Eradication of Septic Shock

Christiana Care Health Services

NCT01449721

COMPLETED 120 participants

Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia

Ohio State University

NCT00806325

COMPLETED 100 participants

Gene Expression Objective Definition of Early Sepsis In Children

Seattle Children's Hospital

NCT06231862

COMPLETED Phase 2 95 participants

Thiamine as a Renal Protective Agent in Septic Shock

Beth Israel Deaconess Medical Center

NCT03550794

COMPLETED Phase 2 94 participants

Inulin for Infections in the Intensive Care Unit

Columbia University

NCT03865706

COMPLETED Phase 4 89 participants

Effect of Nebulized Bronchodilators on Heart Rate

Fahim Khorfan, MD

NCT01151579

COMPLETED 71 participants

REMISE Study: REMnant Biospecimen Investigation in SEpsis

University of Pittsburgh

NCT05684133

COMPLETED Phase 3 65 participants

A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer

National Cancer Institute (NCI)

NCT00001338

COMPLETED NA 60 participants

Pilot Trial of External Warming in Septic Patients

Washington University School of Medicine

NCT02706275

COMPLETED NA 58 participants

Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment

University of Vermont

NCT04067622

COMPLETED 58 participants

Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis

University of Florida

NCT04576819

COMPLETED 52 participants

Longitudinal Gene Expression Profiling in Adults After Traumatic Injury

Stanford University

NCT02656459

COMPLETED 50 participants

Immune Suppression and Ventilator Associated Pneumonias

Matthew Exline

NCT01135277

COMPLETED 50 participants

Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients

Olive View-UCLA Education & Research Institute

NCT02679625

COMPLETED NA 45 participants

Sepsis, Severe Sepsis and Septic Shock Detection by Breath Analysis

Landon Pediatric Foundation

NCT03497182

COMPLETED 45 participants

Methionine Metabolism in Enterally Fed Pediatric Sepsis

The Cleveland Clinic

NCT01889264

COMPLETED 26 participants

Digital Capillary Refill for Monitoring of Sepsis

Oregon Health and Science University

NCT04529655

COMPLETED Phase 1 18 participants

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

Stony Brook University

NCT00004494

COMPLETED Phase 1 18 participants

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

Altor BioScience

NCT01438853

COMPLETED 10 participants

Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis

Stanford University

NCT00185783

COMPLETED Phase 1 9 participants

Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance

Hartford Hospital

NCT04147221

COMPLETED NA 5 participants

Project 4B: Lower Extremity Strength Training in ICU Patients

University of Florida

NCT02467023

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 8
Phase 3 6
Phase 4 4

Named interventions

Most-linked intervention names on Sepsis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
7 trials
Usual Care Other
2 trials
Blood collection Other
2 trials
Active Intervention Other
1 trials
11-gene set Other
1 trials
Muscle Biopsy Medication: Versed Drug
1 trials
Muscle Biopsy Medication: Lidocaine Drug
1 trials
measurement of maximal isometric twitch strength Device
1 trials

US sites by state

Facility locations filed on Sepsis trials. A trial with sites in several states counts in each.

California 16 trials
Florida 14 trials
Ohio 13 trials
New York 12 trials
Massachusetts 12 trials
North Carolina 9 trials
Pennsylvania 8 trials
Michigan 8 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sepsis page

91 registered trials, 33 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sepsis condition card totals 91 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.